Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)
- Not stated
- Not stated
- Nov 22, 2024
Official announcement on the NIH Guide · opens the funder's page. Always confirm dates there.
Or read the full text and all 4 review criteria here, free with an account. Create free account
Summary
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and…
Related NIH announcements
NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
INCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)
The full announcement, free with an account
- The full announcement text, not just the first two sentences
- All 4 review criteria reviewers score this against, extracted from this announcement
On Plus, $39 a month
- The eligibility check against your profile: career stage, institution type, and the windows that close before the deadline does
- Funded precedents: what similar NIH projects received, from the award records in NIH RePORTER
- A Reviewer Scorecard of your draft against these criteria
More from National Institutes of Health
NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)
$500k